Evidence map›Paper›PMID 23346953›Full record

ArticleBiochemistry2013

Diaryl hydrazones as multifunctional inhibitors of amyloid self-assembly.

Béla Török, Abha Sood, Seema Bag, Rekha Tulsan, Sanjukta Ghosh, Dmitry Borkin, Arleen R Kennedy, Michelle Melanson, Richard Madden, Weihong Zhou and 2 more

Abstract read
In one paragraph

Article in Biochemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Evaluation of hydrazone andJournal of enzyme inhibition and medicinal chemistry · 2024
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. 1-(2,4-Di-nitro-phen-yl)-2-[(E)-2,4,5-tri-meth-oxy-benzyl-idene]hydrazine.Acta crystallographica. Section E, Structure reports online · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Béla TörökDepartment of Chemistry, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, MA 02125-3393, USA.
Abha Sood
Seema Bag
Rekha Tulsan
Sanjukta Ghosh
Dmitry Borkin
Arleen R Kennedy
Michelle Melanson
Richard Madden
Weihong Zhou
Harry Levine
Marianna Török

Funding

SYNTHESIS OF NOVEL INHIBITORS OF AMYLOID FIBRILLOGENESISR15AG025777 · NIA · UNIVERSITY OF MASSACHUSETTS BOSTON · PI TOROK, BELA · 2005 to 2009
$393k
A screen for small molecule inhibitors of soluble Abeta oligomer assemblyR21AG028816 · NIA · UNIVERSITY OF KENTUCKY · PI LEVINE, HARRY · 2006 to 2007
$337k
NIA NIH HHS R15 AG025777NIA NIH HHS R-15 AG025777-03A1NIA NIH HHS R21 AG028816NIA NIH HHS R21AG028816-01
6 · The paper itself

Abstract

The design and application of an effective, new class of multifunctional small molecule inhibitors of amyloid self-assembly are described. Several compounds based on the diaryl hydrazone scaffold were designed. Forty-four substituted derivatives of this core structure were synthesized using a variety of benzaldehydes and phenylhydrazines and characterized. The inhibitor candidates were evaluated in multiple assays, including the inhibition of amyloid β (Aβ) fibrillogenesis and oligomer formation and the reverse processes, the disassembly of preformed fibrils and oligomers. Because the structure of the hydrazone-based inhibitors mimics the redox features of the antioxidant resveratrol, the radical scavenging effect of the compounds was evaluated by colorimetric assays against 2,2-diphenyl-1-picrylhydrazyl and superoxide radicals. The hydrazone scaffold was active in all of the different assays. The structure-activity relationship revealed that the substituents on the aromatic rings had a considerable effect on the overall activity of the compounds. The inhibitors showed strong activity in fibrillogenesis inhibition and disassembly, and even greater potency in the inhibition of oligomer formation and oligomer disassembly. Supporting the quantitative fluorometric and colorimetric assays, size exclusion chromatographic studies indicated that the best compounds practically eliminated or substantially inhibited the formation of soluble, aggregated Aβ species, as well. Atomic force microscopy was also applied to monitor the morphology of Aβ deposits. The compounds also possessed the predicted antioxidant properties; approximately 30% of the synthesized compounds showed a radical scavenging effect equal to or better than that of resveratrol or ascorbic acid.

Indexed as

Structure-Activity RelationshipAmyloidAmyloid beta-PeptidesAntioxidantsBiphenyl CompoundsDrug DesignDrug Evaluation, PreclinicalHydrazonesMicroscopy, Atomic ForceMolecular StructurePicratesSuperoxides1,1-diphenyl-2-picrylhydrazylAmyloidAmyloid beta-PeptidesAntioxidantsBiphenyl CompoundsHydrazonesPicratesSuperoxides

Identifiers

PMID23346953
PMCPMC3608202

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.